BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BNT116 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BNT116\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05557591-2104@assetmemo.bio
DTSTAMP:20261121T004538Z
DTSTART;VALUE=DATE:20280126
DTEND;VALUE=DATE:20280127
SUMMARY:BNT116: Phase 2 readout est. (NCT05557591)
DESCRIPTION:BNT116\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Trial 
 to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Work
 s and How Safe the Combination is in Adults With Advanced Non-small Cell L
 ung Cancer (EMPOWERVAX Lung 1)\nEstimated primary completion: 26 January 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/bnt116#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05557591
URL:https://assetmemo.bio/drug/bnt116#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05142189-2104@assetmemo.bio
DTSTAMP:20261121T004538Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:BNT116: Phase 1 readout est. (NCT05142189)
DESCRIPTION:BNT116\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Clinical
  Trial Evaluating the Safety\, Tolerability and Preliminary Efficacy of BN
 T116 Alone and in Combinations in Patients With Advanced Non-small Cell Lu
 ng Cancer\nEstimated primary completion: February 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bnt116#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05142189
URL:https://assetmemo.bio/drug/bnt116#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
